SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
SS-31 (Elamipretide (SS-31)) is researched primarily for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. The first FDA-approved mitochondrial-targeted therapy — directly addressing the fundamental mitochondrial dysfunction underlying multiple age-related and genetic diseases by stabilizing the inner membrane structure itself. It belongs to the Mitochondrial-targeting tetrapeptide category of compounds.
What Is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics.
The first FDA-approved mitochondrial-targeted therapy — directly addressing the fundamental mitochondrial dysfunction underlying multiple age-related and genetic diseases by stabilizing the inner membrane structure itself. It has attracted significant research interest for its potential effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
How Does SS-31 Produce These Benefits?
Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactive oxygen species production, increases ATP generation, and prevents apoptosis through mitochondrial outer membrane stabilization.
This multi-pathway activity is why SS-31 shows potential across several different applications rather than being limited to a single use case.
Can SS-31 Help With Improved Muscle Strength?
Research suggests SS-31 may support improved muscle strength through its mitochondrial-targeting tetrapeptide activity. FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
Protocols targeting improved muscle strength typically use 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion for 12-48 weeks in clinical trials.
Can SS-31 Help With Enhanced Cardiac Function?
Research suggests SS-31 may support enhanced cardiac function through its mitochondrial-targeting tetrapeptide activity. FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
Protocols targeting enhanced cardiac function typically use 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion for 12-48 weeks in clinical trials.
Can SS-31 Help With Increased Atp Production?
Research suggests SS-31 may support increased ATP production through its mitochondrial-targeting tetrapeptide activity. FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
Protocols targeting increased ATP production typically use 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion for 12-48 weeks in clinical trials.
Can SS-31 Help With Reduced Oxidative Stress?
Research suggests SS-31 may support reduced oxidative stress through its mitochondrial-targeting tetrapeptide activity. FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
Protocols targeting reduced oxidative stress typically use 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion for 12-48 weeks in clinical trials.
Can SS-31 Help With Restored Age-Related Mitochondrial Dysfunction?
Research suggests SS-31 may support restored age-related mitochondrial dysfunction through its mitochondrial-targeting tetrapeptide activity. FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
Protocols targeting restored age-related mitochondrial dysfunction typically use 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion for 12-48 weeks in clinical trials.
Can Stacking Enhance SS-31 Benefits?
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.
See our SS-31 stacking guide for detailed combination protocols.
What Is the Bottom Line on SS-31 Benefits?
SS-31 is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. The evidence base includes: FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
SS-31 is fda-approved september 2025 (forzinity) for barth syndrome. phase 3 trials ongoing for other indications. Source from reputable vendors with third-party testing for reliable results.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
- MOTS-C Complete Guide
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.